Skip Nav Destination
Issues
1 August 2011
-
Cover Image
Cover Image
Rodrik-Outmezguine and colleagues identify an adaptive mechanism in the AKT signaling pathway. AKT signaling becomes reactivated through feedback-induced phosphorylation of AKT on T308 but not on S473. The addition of RTK inhibitors prevented reactivation, causing cell death and tumor regression in vivo, highlighting the possible need for combinatorial approaches to block feedback-regulated pathways. For details, please see the article by Rodrik-Outmezguine and colleagues on page 248. - PDF Icon PDF LinkTable of Contents
ISSN 2159-8274
EISSN 2159-8290
In This Issue
News in Brief
News in Depth
Research Watch
Tumor Microenvironment
Tumorigenesis
Glioma
Leukemia
Radiotherapy
Genomics
In the Spotlight
Prospective
Mini Review
Research Articles
Functional Viability Profiles of Breast Cancer
Rachel Brough; Jessica R. Frankum; David Sims; Alan Mackay; Ana M. Mendes-Pereira; Ilirjana Bajrami; Sara Costa-Cabral; Rumana Rafiq; Amar S. Ahmad; Maria Antonietta Cerone; Rachael Natrajan; Rachel Sharpe; Kai-Keen Shiu; Daniel Wetterskog; Konstantine J. Dedes; Maryou B. Lambros; Teeara Rawjee; Spiros Linardopoulos; Jorge S. Reis-Filho; Nicholas C. Turner; Christopher J. Lord; Alan Ashworth
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds